PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
暂无分享,去创建一个
Paola Storici | Cristina Alli | Maurizio Rocchetti | Enrico Pesenti | Luisa Rusconi | Paolo Cappella | D. Ballinari | V. Croci | P. Cappella | E. Pesenti | A. Marsiglio | M. Rocchetti | P. Storici | L. Gianellini | J. Moll | P. Vianello | Dario Ballinari | Anna Degrassi | Aurelio Marsiglio | Daniele Fancelli | Patrizia Carpinelli | Maria Laura Giorgini | Chiara Soncini | Paola Zugnoni | Paola Vianello | V. Patton | Valter Croci | C. Arrigoni | D. Fancelli | G. Texidó | A. Degrassi | P. Carpinelli | R. Ceruti | M. L. Giorgini | L. Rusconi | P. Zugnoni | C. Soncini | Cristina Alli | Roberta Ceruti | Laura Gianellini | Gemma Texido | Claudio Arrigoni | Veronica Patton | Jürgen Moll | M. Giorgini
[1] David Bebbington,et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo , 2004, Nature Medicine.
[2] J. Peters,et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore–microtubule attachment and in maintaining the spindle assembly checkpoint , 2003, The Journal of cell biology.
[3] R. Pazdur,et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] M. Ichihara,et al. The RET proto‐oncogene: A molecular therapeutic target in thyroid cancer , 2005, Cancer science.
[5] Paola Storici,et al. 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. , 2006, Journal of medicinal chemistry.
[6] R. Matusik,et al. Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[7] Chiao-Ying Lin,et al. Overexpression and Amplification of Aurora-A in Hepatocellular Carcinoma , 2004, Clinical Cancer Research.
[8] R. Margolis,et al. Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. , 2001, Molecular biology of the cell.
[9] Dirk Strumberg,et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Stephen S. Taylor,et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores , 2003, The Journal of cell biology.
[11] Richard Bayliss,et al. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. , 2003, Molecular cell.
[12] Wei Chen,et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase , 2007, Proceedings of the National Academy of Sciences.
[13] Chung F. Wong,et al. Exploiting novel cell cycle targets in the development of anticancer agents. , 2005, Current cancer drug targets.
[14] M. Santoro,et al. Point Mutation of the RetProto-oncogene in the TT Human Medullary Thyroid Carcinoma Cell Line , 1995 .
[15] Domenico Coppola,et al. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] H. Kawai,et al. Aurora-B/AIM-1 kinase activity is involved in Ras-mediated cell transformation , 2005, Oncogene.
[17] Antonella Isacchi,et al. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358. , 2007, Cancer research.
[18] E. Scanziani,et al. Magnetic resonance imaging and histopathological characterization of prostate tumors in TRAMP mice as model for pre‐clinical trials , 2007, The Prostate.
[19] R. Motzer,et al. Sunitinib malate for the treatment of solid tumours: a review of current clinical data , 2006, Expert opinion on investigational drugs.
[20] Michael H Atkins,et al. Sunitinib maleate , 2006, Nature Reviews Drug Discovery.
[21] Tong Tong,et al. Overexpression of Aurora-A Contributes to Malignant Development of Human Esophageal Squamous Cell Carcinoma , 2004, Clinical Cancer Research.
[22] A. Balmain,et al. Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. , 2005, Carcinogenesis.
[23] P. Chieffi,et al. 0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(2):928–935 Printed in U.S.A. Copyright © 2005 by The Endocrine Society doi: 10.1210/jc.2004-1518 Aurora B Overexpression Associates with the Thyroid Carcinoma Undifferentiated Phe , 2004 .
[24] S. Wilhelm,et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.
[25] H. Katayama,et al. Mitotic kinase expression and colorectal cancer progression. , 1999, Journal of the National Cancer Institute.
[26] G. Schwartz,et al. Aurora Kinases: New Targets for Cancer Therapy , 2006, Clinical Cancer Research.
[27] J. Harper,et al. Anticancer drug targets: cell cycle and checkpoint control. , 1999, The Journal of clinical investigation.
[28] Randy Allred,et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.
[29] S. Nicosia,et al. Aurora-A Abrogation of p53 DNA Binding and Transactivation Activity by Phosphorylation of Serine 215* , 2004, Journal of Biological Chemistry.
[30] C. Allis,et al. Mitotic Phosphorylation of Histone H3: Spatio-Temporal Regulation by Mammalian Aurora Kinases , 2002, Molecular and Cellular Biology.
[31] W. Earnshaw,et al. The cellular geography of Aurora kinases , 2003, Nature Reviews Molecular Cell Biology.
[32] Hui Yang,et al. Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase , 2005, FEBS letters.
[33] G. Parmigiani,et al. The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.
[34] Paolo Magni,et al. Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents , 2004, Cancer Research.
[35] D. Ballinari,et al. PHA-680632, a Novel Aurora Kinase Inhibitor with Potent Antitumoral Activity , 2006, Clinical Cancer Research.
[36] J. Verweij,et al. Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all? , 2006, European Journal of Cancer.
[37] P. Dobrzanski,et al. The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[38] M. Loda,et al. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. , 2006, Cancer research.
[39] D. Bergstrom,et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. , 2007, Blood.
[40] C. Sawyers,et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. , 2007, The Journal of clinical investigation.
[41] H. Saya,et al. Aurora-A — A guardian of poles , 2005, Nature Reviews Cancer.
[42] L. Mariani,et al. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[43] H. Friess,et al. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[44] A. Strife,et al. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies , 2003, Leukemia.
[45] Rajesh Odedra,et al. AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis , 2007, Clinical Cancer Research.
[46] A. Vulpetti,et al. Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. , 2005, Journal of medicinal chemistry.
[47] Kaori Sasai,et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53 , 2004, Nature Genetics.
[48] Brian Schryver,et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers , 1998, The EMBO journal.
[49] M. Santoro,et al. Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. , 1995, Biochemical and biophysical research communications.
[50] Daniel K. Treiber,et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. , 2006, Cancer research.